<DOC>
	<DOCNO>NCT00996008</DOCNO>
	<brief_summary>This study look safe effective , novel agent , CT 327 cream treat patient mild moderate atopic dermatitis ( AD ) . Patients treat twice daily 14 day specific lesion AD safety symptom AD assess throughout treatment period .</brief_summary>
	<brief_title>CT 327 Treatment Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male Female subject age &gt; 18 year Written inform consent Mild moderate AD baseline ( EASI score least 2 3 ) Active AD ( visible eczema , erythema pruritus ) Presence least four target lesion ( symmetrically ) inclusion ( ideally elbow flexion knee bend ) If female childbearing potential use adequate appropriate form contraception oral contraceptive ; intrauterine device ( IUD ) ; contraceptive injection , implant patch If female , pregnant lactating , intend become pregnant study period Allergy test drug excipients Usage topical corticosteroid topical treatment AD within last two week prior study entry ( include calcineurin inhibitor , topical H1 H2 antihistamine , topical antimicrobial , medicate topical agent ) herbal preparation area select treatment Within 4 week prior study entry , receive systemic treatment atopic dermatitis ( include systemic corticosteroid , nonsteroidal , immunosuppressant , immunomodulating drug , treatment light ) . Presence major medical illness require systemic therapy include cancer Clinical diagnosis bacterial infection skin include impetigo abscess Any clinical relevant ECG abnormality Have clinically significant abnormal clinical laboratory test result screen Received investigational drug take part clinical study within three month prior study History drug , alcohol substance abuse factor limit ability cooperate comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>